Peter Attia· MD
So, >> so patient selection is going to matter. >> Yeah, I think it's going to be huge. So, I think >> and I don't think they've done this yet is that inclusion criteria should be patients that >> present with remarkable glucose hypom metabolism. So, I think that's that's really an important key >> because I mean we know there's people who have brains that are chuck full of amaloid that have are completely sharp and are completely normal. So the amaloid hypothesis has a lot of baggage with it right. So I think tal maybe I think amaloid and we have ptal that we can look at but there's other things in the pipeline. I think the p75 >> receptor >> agonist or amplifier looks pretty promising. Those studies are ongoing. >> and then you know for prevention I think some of these things the >> antibodies do have applications but they also come with a lot of baggage with >> not only the cost and accessibility but cerebral hemorrhage >> something you have to have to consider. So the lowhanging fruit would be a a dietary or more likely >> with this population a a an a ketone metabolic therapy intervention that could be a ketogenic formula that could also you know have a number of different co-actors and other things that can be